Lexeo Therapeutics (LXEO) J.P. Morgan Biotech: CEO Fireside Series – Lexeo Therapeutics (LXEO) summary

Program overviews and clinical progress

• Two lead cardiovascular gene therapy programs are advancing: one for Friedreich's ataxia (FA) cardiomyopathy and another for PKP2 arrhythmogenic cardiomyopathy (ACM), both showing promising early results and moving toward registrational studies.

• The FA program has completed phase 1 enrollment, demonstrated a 25% reduction in left ventricular mass, 60% reduction in troponin, and improvements in both cardiac and neurologic functional scales.

• The PKP2 ACM program has treated six patients across two dose cohorts, with an expansion cohort underway and a data readout expected in the second half of the year.

• Both programs utilize AAVrh.10 capsid, which has shown no complement activation or significant safety events, allowing for lower dosing and minimal immune suppression.

• The company is also advancing a gene therapy for APOE4 homozygous Alzheimer's disease, seeking a partner for further development after positive phase 1/2 biomarker results.

Safety, efficacy, and regulatory alignment

• Safety is prioritized by using the lowest effective dose and a capsid with a favorable safety profile, resulting in no drug-related serious adverse events (SAEs) except one grade 2 SAE in FA.

• The FA program's registrational study will use a 12–16 adult patient cohort, with additional adolescent and pediatric groups, powered by strong effect sizes at higher doses.

• FDA alignment has been reached on endpoints and study design for the FA program, with only the statistical analysis plan pending final written submission.

• The PKP2 ACM program is focused on demonstrating dose response in PKP2 protein restoration and reduction in premature ventricular contractions (PVCs), with a registrational trial discussion targeted for 2026.

• Both programs are designed to build a robust safety database, leveraging experience across more than 30 patients treated with AAVrh.10 for cardiac disease.

Market potential, adoption, and strategic vision

• The FA therapy is positioned to address both cardiac mortality and broader disease manifestations, with potential for broad adoption as safety and efficacy are demonstrated.

• The PKP2 ACM therapy targets a large rare disease population, with early adoption expected among patients with high disease burden and ICD interventions.

• Commercial rollout strategies focus on high-risk groups first, expanding to earlier-stage patients as safety is established.

• The company has extended its cash runway into 2028 following an $80 million equity raise, supporting key data readouts and regulatory milestones.

• Long-term vision centers on building a leadership position in precision cardiac genetic medicine, leveraging AAV and future delivery platforms to address a range of rare and complex cardiac diseases.